<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02030535</url>
  </required_header>
  <id_info>
    <org_study_id>1237.7</org_study_id>
    <secondary_id>2013-002652-32</secondary_id>
    <nct_id>NCT02030535</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers</brief_title>
  <official_title>A Randomised, Placebo-controlled, Double-blind, Single Dose, Cross-over Study to Evaluate the Efficacy and Safety of Orally Inhaled Tiotropium + Olodaterol as Both a Fixed Dose Combination and a Free Combination (Both Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy and safety of orally inhaled
      tiotropium and olodaterol as both a fixed dose combination and a free combination with
      respect to lung function and ECG parameters
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3hours) Response After Single-dose Administration</measure>
    <time_frame>1 hour (h) and 10 min pre-dose and at 15 min, 30 min, 1 h, 2 h and 3 h post-dose</time_frame>
    <description>The response was defined as the change from patient baseline. Patient baseline was the average of the mean pre-dose values (period baseline) on each test day (Visit 2 (Day 1), Visit 3 (Day 22 (±7days)), and Visit 4 (Day 43±7days)).
For patients who did not complete all periods, patient baseline was the average of the available period baselines.
The means presented are the adjusted means.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean (Heart Rate Corrected QT Interval (Using Fredericia Adjustment)) QTcF Interval Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Mean QTcF interval change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak QTcF Interval Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Peak QTcF interval change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Heart Rate Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Mean heart rate change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Heart Rate Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Peak heart rate change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate Change From Patient Baseline at Individual Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Heart rate change from patient baseline at individual post-dose time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean RR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Mean RR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak RR Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Peak RR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RR Change From Patient Baseline at Individual Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>RR change from patient baseline at individual post-dose time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean QT (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Mean QT change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak QT (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Peak QT change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QT Change From Patient Baseline at Individual Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>QT change from patient baseline at individual post-dose time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment)) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Mean QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment))change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment)) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Peak QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment))change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTcB Change From Patient Baseline at Individual Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>QTcB change from patient baseline at individual post-dose time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Mean PR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak PR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Peak PR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR Change From Patient Baseline at Individual Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>PR change from patient baseline at individual post-dose time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean QRS (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Mean QRS change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak QRS (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>Peak QRS change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QRS Change From Patient Baseline at Individual Post-dose Time Points</measure>
    <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
    <description>QRS change from patient baseline at individual post-dose time points</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Tiotropium/Olodaterol FDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive tiotropium and olodaterol in a fixed dose combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tiotropium and Olodaterol FC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patient will receive tiotropium and olodaterol in a free combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patient will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <description>free combination with tiotropium</description>
    <arm_group_label>Tiotropium and Olodaterol FC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>free combination with olodaterol</description>
    <arm_group_label>Tiotropium and Olodaterol FC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>fixed dose combination with olodaterol</description>
    <arm_group_label>Tiotropium/Olodaterol FDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olodaterol</intervention_name>
    <description>fixed dose combination with tiotropium</description>
    <arm_group_label>Tiotropium/Olodaterol FDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  patients must sign informed consent consistent with ICH-GCP guidelines prior to
             participation in the trial, which includes medication washout and restrictions.

          -  Patients must have a diagnosis of COPD and must meet the following spirometric
             criteria:

        Patients must have relatively stable airway obstruction with a post-bronchodilator (10 to
        45 minutes after 400mcg salbutamol) FEV1&gt;30% and &lt; 80% of predicted normal (ECSC, GOLD II -
        III) and a post-bronchodilator FEV1/FVC &lt;70% at Visit 1

          -  Male or female patients, 40 years of age or older.

          -  Patients must be current or ex-smokers with a smoking history of more than 10 pack
             years.

          -  Patients who have never smoked cigarettes must be excluded.

          -  Patients must be able to perform technically acceptable pulmonary function tests
             according to ATS/ERS guidelines and maintain records in a paper diary

          -  Patients must be able to inhale medication in a competent manner from the RESPIMAT
             inhaler and from a metered dose inhaler (MDI).

        Exclusion criteria:

          -  Significant disease other than COPD

          -  Clinically relevant abnormal lab values.

          -  History of asthma.

          -  Diagnosis of thyrotoxicosis

          -  Diagnosis of paroxysmal tachycardia

          -  History of myocardial infarction within 1 year of screening visit

          -  Unstable or life-threatening cardiac arrhythmia

          -  Hospitalization for heart failure within the past year

          -  Known active tuberculosis

          -  Malignancy for which patient has undergone resection, radiation therapy or
             chemotherapy within last five years

          -  History of life-threatening pulmonary obstruction and patients with chronic
             respiratory failure

          -  History of cystic fibrosis

          -  Clinically evident bronchiectasis

          -  History of significant alcohol or drug abuse

          -  Thoracotomy with pulmonary resection

          -  Patients treated with oral or patch ß-adrenergics

          -  Patients treated with oral corticosteroid medication at unstable doses or at doses in
             excess of 10mg prednisolone per day or equivalent

          -  Regular use of daytime oxygen therapy for more than one hour per day

          -  Pulmonary rehabilitation program in the six weeks prior to the screening visit or
             patients currently in a pulmonary rehabilitation program

          -  Investigational drug within one month or six half lives (whichever is greater) prior
             to screening visit

          -  Known hypersensitivity to ß-adrenergic and/or anticholinergic drugs, BAC, EDTA

          -  Pregnant or nursing women

          -  Women of childbearing potential not using a highly effective method of birth control

          -  Patient who have previously been randomized in this study or are currently
             participating in another study

          -  Patients who are unable to comply with pulmonary medication restrictions prior to
             randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1237.7.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.7.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.7.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.7.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Großhansdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.7.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1237.7.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2014</study_first_posted>
  <results_first_submitted>June 19, 2015</results_first_submitted>
  <results_first_submitted_qc>June 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 16, 2015</results_first_posted>
  <disposition_first_submitted>June 25, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>June 25, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 26, 2014</disposition_first_posted>
  <last_update_submitted>June 19, 2015</last_update_submitted>
  <last_update_submitted_qc>June 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>Total number of patients randomised and treated in the study. (This is a cross-over trial consisting of a minimum two-week screening period. After screening, eligible patients were randomly assigned to one of 12 treatment sequences. Each patient received all three treatments as single doses on the three test days. Between test days with single dose administration there are 3-week washout periods.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1 (21 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 2 (21 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3 (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set (TS): This patient set included all randomised patients who were administered study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Total number of patients randomised and treated in the study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Mean (Heart Rate Corrected QT Interval (Using Fredericia Adjustment)) QTcF Interval Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Mean QTcF interval change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Mean (Heart Rate Corrected QT Interval (Using Fredericia Adjustment)) QTcF Interval Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Mean QTcF interval change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="7.1"/>
                    <measurement group_id="O2" value="2.2" spread="6.9"/>
                    <measurement group_id="O3" value="1.9" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak QTcF Interval Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Peak QTcF interval change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Peak QTcF Interval Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Peak QTcF interval change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="8.3"/>
                    <measurement group_id="O2" value="5.7" spread="7.6"/>
                    <measurement group_id="O3" value="5.7" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Heart Rate Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Mean heart rate change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Heart Rate Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Mean heart rate change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="5.2"/>
                    <measurement group_id="O2" value="-2.5" spread="5.5"/>
                    <measurement group_id="O3" value="-3.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Heart Rate Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Peak heart rate change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations (a.m. dosing) via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations (a.m. dosing) via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Heart Rate Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Peak heart rate change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="5.5"/>
                    <measurement group_id="O2" value="-0.3" spread="5.7"/>
                    <measurement group_id="O3" value="-1.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3hours) Response After Single-dose Administration</title>
        <description>The response was defined as the change from patient baseline. Patient baseline was the average of the mean pre-dose values (period baseline) on each test day (Visit 2 (Day 1), Visit 3 (Day 22 (±7days)), and Visit 4 (Day 43±7days)).
For patients who did not complete all periods, patient baseline was the average of the available period baselines.
The means presented are the adjusted means.</description>
        <time_frame>1 hour (h) and 10 min pre-dose and at 15 min, 30 min, 1 h, 2 h and 3 h post-dose</time_frame>
        <population>Full Analysis Set (FAS): This patient set included all patients in the TS who had at least 1 visit (Visit 2(Day1), Visit 3(Day22), or Visit 4(Day43)) with both the period baseline value plus any evaluable post-dose spirometry measurement from the same visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations ante meridiem (a.m.) dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler.</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler.</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3hours) Response After Single-dose Administration</title>
          <description>The response was defined as the change from patient baseline. Patient baseline was the average of the mean pre-dose values (period baseline) on each test day (Visit 2 (Day 1), Visit 3 (Day 22 (±7days)), and Visit 4 (Day 43±7days)).
For patients who did not complete all periods, patient baseline was the average of the available period baselines.
The means presented are the adjusted means.</description>
          <population>Full Analysis Set (FAS): This patient set included all patients in the TS who had at least 1 visit (Visit 2(Day1), Visit 3(Day22), or Visit 4(Day43)) with both the period baseline value plus any evaluable post-dose spirometry measurement from the same visit.</population>
          <units>Litres</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.014" spread="0.016"/>
                    <measurement group_id="O2" value="0.233" spread="0.016"/>
                    <measurement group_id="O3" value="0.266" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; patient baseline and period baseline as covariates; patient as a random effect</p_value_desc>
            <method>Mixed models repeated measures analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom. Compound symmetry covariance structure for within−patient variation</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.219</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.187</ci_lower_limit>
            <ci_upper_limit>0.252</ci_upper_limit>
            <estimate_desc>Tio+Olo 5/5μg minus Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>Mixed effect model repeated measures (MMRM) including fixed effects of treatment and period; patient baseline and period baseline as covariates; patient as a random effect</p_value_desc>
            <method>Mixed models repeated measures analysis</method>
            <method_desc>Kenward−Roger approximation of denominator degrees of freedom. Compound symmetry covariance structure for within−patient variation.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.252</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.220</ci_lower_limit>
            <ci_upper_limit>0.284</ci_upper_limit>
            <estimate_desc>Tiotropium 5μg + Olodaterol 5μg minus Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Descriptive comparison. Statistical Analyses 1 &amp; 2 were included in the hierarchical testing sequence (alpha protected), and analysis 3 was not included in the hierarchical testing sequence (not alpha protected)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.033</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.016</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.065</ci_lower_limit>
            <ci_upper_limit>-0.001</ci_upper_limit>
            <estimate_desc>Tio+Olo 5/5μg minus Tiotropium 5μg + Olodaterol 5μg.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate Change From Patient Baseline at Individual Post-dose Time Points</title>
        <description>Heart rate change from patient baseline at individual post-dose time points</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate Change From Patient Baseline at Individual Post-dose Time Points</title>
          <description>Heart rate change from patient baseline at individual post-dose time points</description>
          <population>Treated set (observed cases)</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="5.2"/>
                    <measurement group_id="O2" value="-2.5" spread="5.5"/>
                    <measurement group_id="O3" value="-2.9" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="5.9"/>
                    <measurement group_id="O2" value="-2.4" spread="5.5"/>
                    <measurement group_id="O3" value="-3.1" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="5.5"/>
                    <measurement group_id="O2" value="-2.6" spread="6.0"/>
                    <measurement group_id="O3" value="-4.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="5.6"/>
                    <measurement group_id="O2" value="-2.4" spread="6.0"/>
                    <measurement group_id="O3" value="-3.9" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean RR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Mean RR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Mean RR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Mean RR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="57.7"/>
                    <measurement group_id="O2" value="29.3" spread="57.1"/>
                    <measurement group_id="O3" value="39.5" spread="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak RR Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Peak RR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Peak RR Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Peak RR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.8" spread="64.3"/>
                    <measurement group_id="O2" value="55.5" spread="59.5"/>
                    <measurement group_id="O3" value="68.0" spread="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RR Change From Patient Baseline at Individual Post-dose Time Points</title>
        <description>RR change from patient baseline at individual post-dose time points</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>RR Change From Patient Baseline at Individual Post-dose Time Points</title>
          <description>RR change from patient baseline at individual post-dose time points</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" spread="62.5"/>
                    <measurement group_id="O2" value="29.7" spread="58.5"/>
                    <measurement group_id="O3" value="31.9" spread="55.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8" spread="68.9"/>
                    <measurement group_id="O2" value="28.1" spread="57.4"/>
                    <measurement group_id="O3" value="33.5" spread="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="59.4"/>
                    <measurement group_id="O2" value="33.0" spread="65.7"/>
                    <measurement group_id="O3" value="50.0" spread="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="62.7"/>
                    <measurement group_id="O2" value="25.2" spread="64.9"/>
                    <measurement group_id="O3" value="44.0" spread="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean QT (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Mean QT change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Mean QT (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Mean QT change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="10.7"/>
                    <measurement group_id="O2" value="6.5" spread="11.1"/>
                    <measurement group_id="O3" value="7.9" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak QT (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Peak QT change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Peak QT (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Peak QT change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="11.5"/>
                    <measurement group_id="O2" value="11.5" spread="11.1"/>
                    <measurement group_id="O3" value="13.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QT Change From Patient Baseline at Individual Post-dose Time Points</title>
        <description>QT change from patient baseline at individual post-dose time points</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>QT Change From Patient Baseline at Individual Post-dose Time Points</title>
          <description>QT change from patient baseline at individual post-dose time points</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="10.7"/>
                    <measurement group_id="O2" value="5.5" spread="11.2"/>
                    <measurement group_id="O3" value="4.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="12.6"/>
                    <measurement group_id="O2" value="6.3" spread="11.8"/>
                    <measurement group_id="O3" value="7.9" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" spread="11.4"/>
                    <measurement group_id="O2" value="7.4" spread="12.0"/>
                    <measurement group_id="O3" value="9.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="12.1"/>
                    <measurement group_id="O2" value="6.7" spread="12.6"/>
                    <measurement group_id="O3" value="9.4" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment)) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Mean QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment))change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Mean QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment)) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Mean QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment))change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="9.0"/>
                    <measurement group_id="O2" value="-0.2" spread="8.6"/>
                    <measurement group_id="O3" value="-1.4" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment)) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Peak QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment))change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Peak QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment)) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Peak QTcB (Heart Rate Corrected QT Interval (Using Bazett Adjustment))change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="10.7"/>
                    <measurement group_id="O2" value="4.2" spread="9.7"/>
                    <measurement group_id="O3" value="3.5" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QTcB Change From Patient Baseline at Individual Post-dose Time Points</title>
        <description>QTcB change from patient baseline at individual post-dose time points</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>QTcB Change From Patient Baseline at Individual Post-dose Time Points</title>
          <description>QTcB change from patient baseline at individual post-dose time points</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="9.0"/>
                    <measurement group_id="O2" value="-1.4" spread="8.8"/>
                    <measurement group_id="O3" value="-2.6" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="9.9"/>
                    <measurement group_id="O2" value="-0.2" spread="8.7"/>
                    <measurement group_id="O3" value="-0.0" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="11.3"/>
                    <measurement group_id="O2" value="0.1" spread="10.3"/>
                    <measurement group_id="O3" value="-2.2" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="9.9"/>
                    <measurement group_id="O2" value="0.7" spread="9.8"/>
                    <measurement group_id="O3" value="-0.7" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Mean PR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Mean PR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="4.9"/>
                    <measurement group_id="O2" value="1.6" spread="6.3"/>
                    <measurement group_id="O3" value="1.4" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak PR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Peak PR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination) Olodaterol: 5 μg (2.5 μg per actuation) Tiotropium: 5 μg (2.5 μg per actuation) 2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Peak PR (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Peak PR change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="4.8"/>
                    <measurement group_id="O2" value="4.6" spread="5.9"/>
                    <measurement group_id="O3" value="4.7" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PR Change From Patient Baseline at Individual Post-dose Time Points</title>
        <description>PR change from patient baseline at individual post-dose time points</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>PR Change From Patient Baseline at Individual Post-dose Time Points</title>
          <description>PR change from patient baseline at individual post-dose time points</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="5.9"/>
                    <measurement group_id="O2" value="1.2" spread="7.3"/>
                    <measurement group_id="O3" value="-0.2" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="6.0"/>
                    <measurement group_id="O2" value="2.5" spread="8.4"/>
                    <measurement group_id="O3" value="1.4" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="6.5"/>
                    <measurement group_id="O2" value="0.8" spread="6.3"/>
                    <measurement group_id="O3" value="1.9" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="5.4"/>
                    <measurement group_id="O2" value="1.9" spread="5.4"/>
                    <measurement group_id="O3" value="2.7" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean QRS (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Mean QRS change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Mean QRS (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Mean QRS change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.3"/>
                    <measurement group_id="O2" value="0.1" spread="1.5"/>
                    <measurement group_id="O3" value="0.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak QRS (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
        <description>Peak QRS change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>Peak QRS (Time Interval of ECG) Change From Patient Baseline Over All Post-dose Time Points</title>
          <description>Peak QRS change from patient baseline over all post-dose time points (5min, 10min, 25min and 50min)</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.5"/>
                    <measurement group_id="O2" value="0.9" spread="1.5"/>
                    <measurement group_id="O3" value="1.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QRS Change From Patient Baseline at Individual Post-dose Time Points</title>
        <description>QRS change from patient baseline at individual post-dose time points</description>
        <time_frame>40 min pre-dose and at 5 min, 10 min, 25 min and 50 min post-dose</time_frame>
        <population>Treated set (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
          </group>
          <group group_id="O2">
            <title>Tio+Olo 5/5μg</title>
            <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation.
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
          <group group_id="O3">
            <title>Tiotropium 5μg + Olodaterol 5μg</title>
            <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination (FC) (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing via RESPIMAT® inhaler</description>
          </group>
        </group_list>
        <measure>
          <title>QRS Change From Patient Baseline at Individual Post-dose Time Points</title>
          <description>QRS change from patient baseline at individual post-dose time points</description>
          <population>Treated set (observed cases)</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>5 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.5"/>
                    <measurement group_id="O2" value="-0.2" spread="1.8"/>
                    <measurement group_id="O3" value="-0.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.6"/>
                    <measurement group_id="O2" value="0.1" spread="1.6"/>
                    <measurement group_id="O3" value="0.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.4"/>
                    <measurement group_id="O2" value="0.1" spread="1.6"/>
                    <measurement group_id="O3" value="0.0" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="1.7"/>
                    <measurement group_id="O2" value="0.2" spread="1.7"/>
                    <measurement group_id="O3" value="0.2" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) occurring up to the minimum of 21 days after drug stop date or the start of the next treatment period were considered on treatment; Up to 64 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Single test dose of oral inhalation of Placebo via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
        </group>
        <group group_id="E2">
          <title>Tio+Olo FDC</title>
          <description>Single test dose of oral inhalation of Tio+Olo FDC(fixed dose combination) (5/5 μg) inhalation solution as fixed dose inhalation solution (Tio+Olo FDC) 2.5 μg each per actuation via RESPIMAT inhaler.
2 inhalations a.m. dosing.</description>
        </group>
        <group group_id="E3">
          <title>Tiotropium and Olodaterol FC</title>
          <description>Single test dose of oral inhalation of tiotropium (5 μg) and olodaterol (5 μg) free combination FC (Tio/Olo free combination)
Olodaterol: 5 μg (2.5 μg per actuation)
Tiotropium: 5 μg (2.5 μg per actuation)
2 inhalations a.m. dosing.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information&quot;.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

